Stocktoria

Sagimet Biosciences Inc. SGMT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-07-14 · LEI

Sagimet Biosciences Inc. statistics & valuation

Market cap$432.0M
P / B3.9×
Return on equity-45.8%
Return on capital-51.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2022202320242025
Operating margin (%)
-1537.00% 2022202320242025
Return on equity (%)
-30.60% -29.20% -45.80% 2022202320242025
Shares outstanding
185084 10.5M 31.4M 32.3M 2022202320242025
Net debt ($)
2022202320242025
Share buybacks ($)
2022202320242025
Return on assets (%)
-92.30% -28.80% -28.40% -43.80% 2022202320242025
Free cash flow margin (%)
2022202320242025
Debt / equity (×)
2022202320242025
EPS ($)
-$165.20 -$2.66 -$1.45 -$1.58 2022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022
Operating margin——-1537.0%—
Net margin——-1393.8%—
Return on assets-43.8%-28.4%-28.8%-92.3%
Return on equity-45.8%-29.2%-30.6%16.3%
Current ratio22.8234.3017.096.21

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.